Indeed, Su et al. employing Genidicine®, a gene therapy product approved in 2003 by the China Food and Drug Administration (CFDA) for head and neck cancer gene therapy [143], showed that the injection of a recombinant human adenovirus engineered to express wild-type p53 gene (rArd-p53) in cervical cancer patients, may lead to an increased 5-year overall survival rate [105]. The gene discussed is TP53; the disease is cervical cancer.